Tianjin Tianyao Pharmaceuticals Co Ltd - Asset Resilience Ratio

Latest as of March 2023: 0.00%

Tianjin Tianyao Pharmaceuticals Co Ltd (600488) has an Asset Resilience Ratio of 0.00% as of March 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 600488 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥128.80K
≈ $18.85K USD Cash + Short-term Investments

Total Assets

CN¥6.62 Billion
≈ $968.90 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2001–2015)

This chart shows how Tianjin Tianyao Pharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 600488 total assets.

Liquid Assets Composition Over Time

This chart breaks down Tianjin Tianyao Pharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 600488 long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥128.80K 0.0%
Total Liquid Assets CN¥128.80K 0.00%

Asset Resilience Insights

  • Limited Liquidity: Tianjin Tianyao Pharmaceuticals Co Ltd maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Tianjin Tianyao Pharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio

Compare Tianjin Tianyao Pharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
Drug Manufacturers - Specialty & Generic 2.79%
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 2.51%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Harbin Pharmaceutical Group Co Ltd
SHG:600664
Drug Manufacturers - Specialty & Generic 0.97%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%

Annual Asset Resilience Ratio for Tianjin Tianyao Pharmaceuticals Co Ltd (2001–2015)

The table below shows the annual Asset Resilience Ratio data for Tianjin Tianyao Pharmaceuticals Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2015-12-31 4.95% CN¥150.00 Million
≈ $21.95 Million
CN¥3.03 Billion
≈ $443.85 Million
+4.90pp
2003-12-31 0.05% CN¥758.82K
≈ $111.04K
CN¥1.60 Billion
≈ $234.85 Million
-17.21pp
2002-12-31 17.26% CN¥244.90 Million
≈ $35.84 Million
CN¥1.42 Billion
≈ $207.65 Million
+2.70pp
2001-12-31 14.55% CN¥165.06 Million
≈ $24.15 Million
CN¥1.13 Billion
≈ $165.94 Million
--
pp = percentage points

About Tianjin Tianyao Pharmaceuticals Co Ltd

SHG:600488 China Drug Manufacturers - Specialty & Generic
Market Cap
$979.44 Million
CN¥6.69 Billion CNY
Market Cap Rank
#9107 Global
#2276 in China
Share Price
CN¥6.13
Change (1 day)
-2.54%
52-Week Range
CN¥3.71 - CN¥7.79
All Time High
CN¥7.79
About

Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company's primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, and betamethasone product series. The company provides amino acid r… Read more